Home / BusinessBusinessFinancial TimesBusinessFinancial Times·Aug 3, 2026·1 min readAstraZeneca investors raise concerns over mega-merger talksShareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers SquibbView original source — Financial Times ↗ShareCopy linkShare on XShare on FacebookRelated storiesBusinessCNBCBusinessAug 3, 2026 · 1 minTrump says Exxon and Chevron made 'too much money' off high oil prices during Iran conflict: 'I don't like it'CNBCBusinessABC NewsBusinessAug 3, 2026 · 1 minKeen to invest but don't know where to start? Our expert breaks it downABC NewsBusinessRio TimesBusinessAug 3, 2026 · 1 minAsia Intelligence Brief — Monday, August 3, 2026Rio TimesBusinessRio TimesBusinessAug 3, 2026 · 1 minEurope Intelligence Brief — Monday, August 3, 2026Rio Times
BusinessCNBCBusinessAug 3, 2026 · 1 minTrump says Exxon and Chevron made 'too much money' off high oil prices during Iran conflict: 'I don't like it'CNBC
BusinessABC NewsBusinessAug 3, 2026 · 1 minKeen to invest but don't know where to start? Our expert breaks it downABC News
BusinessRio TimesBusinessAug 3, 2026 · 1 minAsia Intelligence Brief — Monday, August 3, 2026Rio Times
BusinessRio TimesBusinessAug 3, 2026 · 1 minEurope Intelligence Brief — Monday, August 3, 2026Rio Times